Merck & Co., Inc. (ETR:6MK)
70.50
+0.20 (0.28%)
Jun 13, 2025, 5:35 PM CET
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
€799,198
Profits / Employee
€217,972
Market Cap
177.50B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 90,587 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 24,363 |
Merck & Co. News
- 1 day ago - Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI (atinvicitinib) Tablets for Dogs - Wallstreet:Online
- 1 day ago - Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs - Business Wire
- 1 day ago - RFK Jr’s new vaccine advisor has reportedly served as expert witness against Merck vaccine - Seeking Alpha
- 1 day ago - Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine - Reuters
- 1 day ago - Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha
- 1 day ago - Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 - Business Wire
- 1 day ago - Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Wallstreet:Online
- 1 day ago - Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Business Wire